carmustine has been researched along with Graft vs Host Disease in 25 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Graft vs Host Disease: The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this retrospective study, we reviewed outcomes of 22 patients with recurrent and refractory NHL who underwent alloHCT with myeloablative BEAM conditioning and received tacrolimus/sirolimus as graft-versus-host disease (GVHD) prophylaxis at City of Hope between 2005 and 2018." | 9.30 | Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis. ( Ali, H; Budde, E; Chen, R; Forman, SJ; Herrera, AF; Mei, M; Mokhtari, S; Nademanee, A; Nakamura, R; Popplewell, L; Salhotra, A; Sandhu, K; Stiller, T; Zain, J, 2019) |
| "Allogeneic stem cell transplant (SCT) after high-dose conditioning with BEAM/fludarabine/total body irradiation (TBI) in patients with relapsed or refractory lymphoma has shown promising results in a pilot study." | 9.17 | Allogeneic stem cell transplantation for relapsed or refractory lymphoma after conditioning with BEAM/fludarabine/TBI. ( Bucher, C; Buser, A; Gerull, S; Halter, J; Heim, D; O'Meara, A; Passweg, J; Stern, M, 2013) |
| "The combination of carmustine, etoposide, cytarabine and melphalan (BEAM) is an effective autologous transplantation preparative regimen for lymphoma and has little toxicity, but the feasibility and tolerance of BEAM as a preparative regimen for allogeneic transplantation has not been established." | 7.70 | Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. ( Anderlini, P; Andersson, B; Braunschweig, I; Champlin, R; Claxton, D; Cleary, K; Donato, M; Folloder, J; Gajewski, J; Giralt, S; Hagemeister, F; Khouri, I; Körbling, M; Mehra, R; Molldrem, J; Przepiorka, D; Samuels, B; Ueno, NT; van Besien, K, 1999) |
| " In this retrospective study, we reviewed outcomes of 22 patients with recurrent and refractory NHL who underwent alloHCT with myeloablative BEAM conditioning and received tacrolimus/sirolimus as graft-versus-host disease (GVHD) prophylaxis at City of Hope between 2005 and 2018." | 5.30 | Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis. ( Ali, H; Budde, E; Chen, R; Forman, SJ; Herrera, AF; Mei, M; Mokhtari, S; Nademanee, A; Nakamura, R; Popplewell, L; Salhotra, A; Sandhu, K; Stiller, T; Zain, J, 2019) |
| "Allogeneic stem cell transplant (SCT) after high-dose conditioning with BEAM/fludarabine/total body irradiation (TBI) in patients with relapsed or refractory lymphoma has shown promising results in a pilot study." | 5.17 | Allogeneic stem cell transplantation for relapsed or refractory lymphoma after conditioning with BEAM/fludarabine/TBI. ( Bucher, C; Buser, A; Gerull, S; Halter, J; Heim, D; O'Meara, A; Passweg, J; Stern, M, 2013) |
| " Between March 1993 and June 2002, we treated 33 relapsed acute myelogenous leukemia (AML) patients with busulfan-based preparative regimens and selective TCD." | 5.11 | CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens. ( Andresen, S; Ball, E; Bolwell, B; Cook, D; Kalaycio, M; Kuczkowski, E; Pohlman, B; Rybicki, L; Sobecks, R, 2005) |
| " Graft-versus-host disease prophylaxis consisted of cyclosporine A and alemtuzumab (10-20 mg)." | 3.78 | Radiation-free allogeneic conditioning with fludarabine, carmustine, and thiotepa for acute lymphoblastic leukemia and other hematologic malignancies necessitating enhanced central nervous system activity. ( Bertz, H; Christopoulos, P; Finke, J; Ihorst, G; Marks, R; Wäsch, R, 2012) |
| "The combination of carmustine, etoposide, cytarabine and melphalan (BEAM) is an effective autologous transplantation preparative regimen for lymphoma and has little toxicity, but the feasibility and tolerance of BEAM as a preparative regimen for allogeneic transplantation has not been established." | 3.70 | Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. ( Anderlini, P; Andersson, B; Braunschweig, I; Champlin, R; Claxton, D; Cleary, K; Donato, M; Folloder, J; Gajewski, J; Giralt, S; Hagemeister, F; Khouri, I; Körbling, M; Mehra, R; Molldrem, J; Przepiorka, D; Samuels, B; Ueno, NT; van Besien, K, 1999) |
| " In an attempt to reduce the high procedure-related mortality reported with allografting in lymphoma, we have used BEAM (BCNU, etoposide, cytarabine and melphalan), a standard conditioning regimen for autologous transplantation." | 3.70 | Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity. ( Byrne, JL; Carter, GI; Cull, GM; Hale, G; Haynes, AP; Miflin, G; Rebello, P; Russell, NH; Waldmann, H, 2000) |
| "Mini-BEAM/HSC is an effective treatment for lymphoma relapses after allogeneic HSCT, but optimal strategies of remission consolidation and prevention of treatment-related complications are needed to improve outcome." | 1.32 | Treatment of lymphoma relapses after allogeneic hematopoietic stem cell transplantation with intensive chemotherapy followed by infusion of hematopoietic stem cell from the original donor. ( Au, WY; Chan, EC; Kwong, YL; Leung, AY; Liang, R; Lie, AK; Ooi, GC; Siu, LL, 2003) |
| "The probability of disease progression at 1 year for patients with chemoresistant and chemosensitive disease were 75% and 25%, respectively (P =." | 1.31 | Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. ( Carella, A; de Elvira, CR; Goldstone, AH; Mackinnon, S; Robinson, SP; Russell, N; Schmitz, N; Taghipour, G, 2002) |
| "Eleven patients with acute myeloblastic leukemia (AML) beyond the first complete remission or chronic myelogenous leukemia (CML) not in first chronic phase received an association of 13." | 1.29 | Total body irradiation and high-dose cyclophosphamide, BCNU and VP-16 (CBV) as a new preparatory regimen for allogeneic bone marrow transplantation in patients with advanced hematologic malignancies. ( Bourdin, S; Harousseau, JL; Le Tortorec, S; Mahe, B; Mahe, JM; Mechinaud-Lacroix, F; Milpied, N; Moreau, P; Rapp, MJ; Wu, DP, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.00) | 18.7374 |
| 1990's | 4 (16.00) | 18.2507 |
| 2000's | 13 (52.00) | 29.6817 |
| 2010's | 7 (28.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jain, T | 1 |
| Kunze, KL | 1 |
| Temkit, M | 1 |
| Partain, DK | 1 |
| Patnaik, MS | 1 |
| Slack, JL | 1 |
| Khera, N | 1 |
| Hogan, WJ | 1 |
| Roy, V | 1 |
| Noel, P | 1 |
| Leis, JF | 1 |
| Sproat, LZ | 1 |
| Fauble, V | 1 |
| Mesa, RA | 1 |
| Palmer, J | 1 |
| Salhotra, A | 1 |
| Mei, M | 1 |
| Stiller, T | 1 |
| Mokhtari, S | 1 |
| Herrera, AF | 1 |
| Chen, R | 1 |
| Popplewell, L | 1 |
| Zain, J | 1 |
| Ali, H | 1 |
| Sandhu, K | 1 |
| Budde, E | 1 |
| Nademanee, A | 1 |
| Forman, SJ | 1 |
| Nakamura, R | 1 |
| Garfin, PM | 1 |
| Link, MP | 1 |
| Donaldson, SS | 1 |
| Advani, RH | 1 |
| Luna-Fineman, S | 1 |
| Kharbanda, S | 1 |
| Porteus, M | 1 |
| Weinberg, KI | 1 |
| Agarwal-Hashmi, R | 1 |
| Hu, M | 1 |
| Kramer, B | 1 |
| Zhang, GY | 1 |
| Wang, YM | 1 |
| Watson, D | 1 |
| Howden, B | 1 |
| McCowage, G | 1 |
| Alexander, IE | 1 |
| Gunning, P | 1 |
| Alexander, SI | 1 |
| Rabitsch, W | 1 |
| Bojic, M | 1 |
| Wohlfarth, P | 1 |
| Leiner, M | 1 |
| Schörgenhofer, C | 1 |
| Kalhs, P | 1 |
| Schulenburg, A | 1 |
| Sillaber, C | 1 |
| Mitterbauer, M | 1 |
| Sperr, WR | 1 |
| Jäger, U | 1 |
| Skrabs, K | 1 |
| Greinix, H | 1 |
| Hermann, A | 1 |
| Lamm, W | 1 |
| Christopoulos, P | 1 |
| Bertz, H | 2 |
| Ihorst, G | 1 |
| Marks, R | 1 |
| Wäsch, R | 2 |
| Finke, J | 2 |
| O'Meara, A | 1 |
| Halter, J | 2 |
| Heim, D | 2 |
| Gerull, S | 1 |
| Bucher, C | 2 |
| Passweg, J | 1 |
| Buser, A | 1 |
| Stern, M | 2 |
| Lush, RJ | 1 |
| Haynes, AP | 3 |
| Byrne, J | 1 |
| Cull, GM | 2 |
| Carter, GI | 2 |
| Pagliuca, A | 2 |
| Parker, JE | 1 |
| Mufti, G | 1 |
| Mahendra, P | 1 |
| Craddock, CF | 1 |
| Lui Yin, JA | 1 |
| Garg, M | 1 |
| Prentice, HG | 1 |
| Potter, MN | 1 |
| Russell, NH | 3 |
| Marks, DI | 1 |
| Lush, R | 1 |
| Cavenagh, J | 1 |
| Milligan, DW | 1 |
| Schey, S | 1 |
| Parker, A | 1 |
| Clark, FJ | 1 |
| Hunt, L | 1 |
| Yin, J | 1 |
| Fuller, S | 1 |
| Vandenberghe, E | 1 |
| Marsh, J | 1 |
| Littlewood, T | 1 |
| Smith, GM | 1 |
| Culligan, D | 1 |
| Hunter, A | 1 |
| Chopra, R | 1 |
| Davies, A | 1 |
| Towlson, K | 1 |
| Williams, CD | 1 |
| Robinson, SP | 1 |
| Goldstone, AH | 2 |
| Mackinnon, S | 1 |
| Carella, A | 1 |
| Russell, N | 1 |
| de Elvira, CR | 1 |
| Taghipour, G | 1 |
| Schmitz, N | 1 |
| Rossi, HA | 1 |
| Becker, PS | 1 |
| Emmons, RV | 1 |
| Westervelt, P | 1 |
| Levy, W | 1 |
| Liu, Q | 1 |
| Clark, Y | 1 |
| Ballen, K | 1 |
| Au, WY | 1 |
| Lie, AK | 1 |
| Siu, LL | 1 |
| Chan, EC | 1 |
| Ooi, GC | 1 |
| Leung, AY | 1 |
| Liang, R | 1 |
| Kwong, YL | 1 |
| Kalaycio, M | 1 |
| Rybicki, L | 1 |
| Pohlman, B | 1 |
| Sobecks, R | 1 |
| Ball, E | 1 |
| Cook, D | 1 |
| Andresen, S | 1 |
| Kuczkowski, E | 1 |
| Bolwell, B | 1 |
| Rao, PS | 1 |
| Law, LY | 1 |
| Horning, SJ | 1 |
| Wong, RM | 1 |
| Johnston, LJ | 1 |
| Laport, GG | 1 |
| Lowsky, R | 1 |
| Shizuru, JA | 1 |
| Blume, KG | 1 |
| Negrin, RS | 1 |
| Stockerl-Goldstein, KE | 1 |
| Buser, AS | 1 |
| Arber, C | 1 |
| Meyer-Monard, S | 1 |
| Stussi, G | 1 |
| Lohri, A | 1 |
| Ghielmini, M | 1 |
| Tichelli, A | 1 |
| Passweg, JR | 1 |
| Gratwohl, A | 1 |
| Vigouroux, S | 1 |
| Michallet, M | 1 |
| Porcher, R | 1 |
| Attal, M | 1 |
| Ades, L | 1 |
| Bernard, M | 1 |
| Blaise, D | 1 |
| Tabrizi, R | 1 |
| Garban, F | 1 |
| Cassuto, JP | 1 |
| Chevalier, P | 1 |
| Facon, T | 1 |
| Ifrah, N | 1 |
| Renaud, M | 1 |
| Tilly, H | 1 |
| Vernant, JP | 1 |
| Kuentz, M | 1 |
| Bourhis, JH | 1 |
| Bordigoni, P | 1 |
| Deconinck, E | 1 |
| Lioure, B | 1 |
| Socié, G | 1 |
| Milpied, N | 2 |
| Ingram, W | 1 |
| Devereux, S | 1 |
| Das-Gupta, EP | 1 |
| Byrne, JL | 2 |
| Shaw, BE | 1 |
| McMillan, A | 1 |
| Gonzalez, J | 1 |
| Ho, A | 1 |
| Mufti, GJ | 1 |
| Castenskiold, EC | 1 |
| Kelsey, SM | 1 |
| Collins, PW | 1 |
| Coldwell, RD | 1 |
| Allen, PD | 1 |
| Side, LE | 1 |
| Makin, HL | 1 |
| Newland, AC | 1 |
| Wu, DP | 1 |
| Moreau, P | 1 |
| Mechinaud-Lacroix, F | 1 |
| Mahe, B | 1 |
| Le Tortorec, S | 1 |
| Rapp, MJ | 1 |
| Bourdin, S | 1 |
| Mahe, JM | 1 |
| Harousseau, JL | 1 |
| Barta, A | 1 |
| Batai, A | 1 |
| Torbagyi, E | 1 |
| Sipos, A | 1 |
| Lengyel, L | 1 |
| Petranyi, GG | 1 |
| Paloczi, K | 1 |
| Kelemen, E | 1 |
| Przepiorka, D | 1 |
| van Besien, K | 1 |
| Khouri, I | 1 |
| Hagemeister, F | 1 |
| Samuels, B | 1 |
| Folloder, J | 1 |
| Ueno, NT | 1 |
| Molldrem, J | 1 |
| Mehra, R | 1 |
| Körbling, M | 1 |
| Giralt, S | 1 |
| Gajewski, J | 1 |
| Donato, M | 1 |
| Cleary, K | 1 |
| Claxton, D | 1 |
| Braunschweig, I | 1 |
| Andersson, B | 1 |
| Anderlini, P | 1 |
| Champlin, R | 1 |
| Miflin, G | 1 |
| Rebello, P | 1 |
| Hale, G | 1 |
| Waldmann, H | 1 |
| Reisser, S | 1 |
| Hahn, J | 1 |
| Engelhardt, M | 1 |
| Kunzmann, R | 1 |
| Veelken, H | 1 |
| Holler, E | 2 |
| Kolb, HJ | 1 |
| Bender-Götze, C | 1 |
| Haas, RJ | 1 |
| Thierfelder, S | 1 |
| Wilmanns, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I/II Trial of Donor Derived Cytokine Induced Killer (CIK) Cells Infusion for Relapsed Hematologic Malignancy After Haploidentical Stem Cell Transplantation[NCT03821519] | Phase 1/Phase 2 | 20 participants (Anticipated) | Interventional | 2019-01-13 | Recruiting | ||
| Safety and Efficacy of a Strategy of Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Chemosensitive Relapsed Follicular Lymphoma[NCT01208896] | Phase 2 | 32 participants (Actual) | Interventional | 2011-02-03 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 trials available for carmustine and Graft vs Host Disease
| Article | Year |
|---|---|
Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis.
Topics: Adolescent; Adult; Allografts; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabin | 2019 |
Allogeneic stem cell transplantation for relapsed or refractory lymphoma after conditioning with BEAM/fludarabine/TBI.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival | 2013 |
Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion.
Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodie | 2001 |
High-dose cyclophosphamide, BCNU, and VP-16 (CBV) conditioning before allogeneic stem cell transplantation for patients with non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Blood Plate | 2003 |
CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Carmus | 2005 |
High-dose chemotherapy using BEAM without autologous rescue followed by reduced-intensity conditioning allogeneic stem-cell transplantation for refractory or relapsing lymphomas: a comparison of delayed versus immediate transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Graft vs | 2007 |
Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclosporine; Female; Follow-Up S | 2000 |
Bone marrow transplantation for the treatment of leukaemia-results of the Munich Cooperative Group.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Carmustine; Child; Child, Preschool; Cyclophosphamid | 1989 |
17 other studies available for carmustine and Graft vs Host Disease
| Article | Year |
|---|---|
Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis.
Topics: Adult; Aged; Antineoplastic Agents; Busulfan; Carmustine; Chimerism; Female; Graft vs Host Disease; | 2019 |
Improved outcomes after autologous bone marrow transplantation for children with relapsed or refractory Hodgkin lymphoma: twenty years experience at a single institution.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Carmustine; Child; Cyclophosphamide; Etoposide; Fema | 2015 |
Methyl-Guanine-Methyl-Transferase Transgenic Bone Marrow Transplantation Allows N,N-bis(2-chloroethyl)-Nitrosourea Driven Donor Mixed-Chimerism Without Graft-Versus-Host Disease, and With Donor-Specific Allograft Tolerance.
Topics: Animals; Antineoplastic Agents, Alkylating; Bone Marrow Transplantation; Carmustine; Disease Models, | 2015 |
Alemtuzumab-BEAM as conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma: a single-center analysis.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocol | 2016 |
Radiation-free allogeneic conditioning with fludarabine, carmustine, and thiotepa for acute lymphoblastic leukemia and other hematologic malignancies necessitating enhanced central nervous system activity.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Carmustine; Central Nervous System; Cyc | 2012 |
The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neo | 2002 |
Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neo | 2002 |
Treatment of lymphoma relapses after allogeneic hematopoietic stem cell transplantation with intensive chemotherapy followed by infusion of hematopoietic stem cell from the original donor.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Gr | 2003 |
Nephrotic syndrome in patients with peripheral blood stem cell transplant.
Topics: Acute Kidney Injury; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineop | 2005 |
High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cause of Death; Combined Modality | 2006 |
Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).
Topics: Adult; Aged; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Prot | 2007 |
Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma.
Topics: Acute Disease; Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2008 |
Functional hyperactivity of monocytes after bone marrow transplantation: possible relevance for the development of post-transplant complications or relapse.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biopterins; Bone Marr | 1995 |
Total body irradiation and high-dose cyclophosphamide, BCNU and VP-16 (CBV) as a new preparatory regimen for allogeneic bone marrow transplantation in patients with advanced hematologic malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1994 |
Haemopoietic cell transplantation activity and results: a single institution experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Graft vs Host Disease; Hemat | 1998 |
Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Female; Graft vs Host | 1999 |
Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; | 2000 |